Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK delivers Q3 sales of £7.8 billion, +4% AER, +2% CER
Total EPS 24.8p, +49% AER, +46% CER; Adjusted EPS 32.5p, +3% AER, flat CER
-
Shingrix approved in the US for prevention of shingles in adults aged 50 and over
Pooled clinical trial results showed > 90 percent efficacy across all age groups
-
GSK receives World Health Organization Prequalification for Synflorix pneumococcal vaccine four-dose vial
WHO awarded prequalification for the new four-dose vial presentation of Synflorix pneumococcal vaccine targeting GAVI supported countries.
-
GSK announces first approval of Shingrix in Canada
The only shingles vaccine to achieve ≥90% efficacy in adults aged 50 and over
-
GSK receives approval for Benlysta in Japan for the treatment of systemic lupus erythematosus
GSK announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Benlysta (belimumab)
-
GSK and Innoviva report positive headline results from IMPACT study showing single inhaler triple therapy Trelegy Ellipta reduced COPD exacerbations
Trelegy Ellipta met study primary endpoint
-
Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US
GlaxoSmithKline plc and Innoviva, Inc. announced the US Food and Drug Administration has approved once-daily, single inhaler triple therapy
-
Trelegy Ellipta once-daily single inhaler triple therapy receives positive opinion from the CHMP in Europe for appropriate patients with COPD
EMA CHMP issues positive opinion for Trelegy Ellipta.
-
GSK receives CHMP positive opinion for self-injectable formulation of Benlysta for systemic lupus erythematosus
GSK today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion
-
FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over
The data supports the efficacy and safety of Shingrix for the prevention of herpes zoster (shingles) in adults ages 50 and over.
-
GSK announces phase III results published in NEJM of mepolizumab in patients with eosinophilic COPD at risk of exacerbations
GlaxoSmithKline plc announced the results from the phase III studies for mepolizumab in chronic obstructive pulmonary disease (COPD).
-
Positive results from pioneering Salford Lung Study in asthma published in The Lancet, and presented at European Respiratory Congress
Relvar Ellipta was superior to usual care treatment in improving asthma control for patients in Salford Lung Study.
-
GSK exercises option on phase I/II NY-ESO T-cell therapy (GSK3377794)
Today GSK announced that it has exercised the option to obtain an exclusive global license from Adaptimmune
-
GSK presents respiratory data from pipeline to clinical practice at ERS
45 abstracts will be shared about current and future treatments for patients with respiratory diseases
-
GSK responds to UK Life Sciences Industrial Strategy
Read our response to the UK Life Sciences Industrial Strategy.
-
GSK delivers further progress in Q2 and sets out new priorities for the Group
Q2 was another quarter of progress for GSK with Group sales up 3% to £7.3 billion and Adjusted EPS of 27.2p.
-
ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings
ViiV, specialist HIV company, majority owned by GSK, Pfizer & Shionogi announced positive interim results from DAWNING.
-
Karenann Terrell appointed Chief Digital & Technology Officer, GSK
GSK today announced that Karenann Terrell has been appointed Chief Digital & Technology Officer
-
Switching to a dolutegravir regimen from a boosted protease inhibitor regimen maintained viral suppression and improved lipid fractions in patients with HIV and high cardiovascular risk
ViiV Healthcare and NEAT-ID announced results from the NEAT 022 study of more than 400 patients with HIV and high cardiovascular risk
-
Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen of long-acting cabotegravir and rilpivirine and a three-drug regimen in patients with HIV
LATTE-2 study results published in The Lancet and presented at International AIDS Society Meeting
